简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

司法部称将加强对受Archegos倒闭打击的银行的审查

2024-09-17 21:54

The U.S. Department of Justice is beefing up its investigation into banks that collectively lost billions of dollars following the meltdown of Bill Hwang’s Archegos Capital Management in 2021, according to a Tuesday media report.

The news comes just a couple of months after Hwang had been convicted of fraud and market manipulation that led to the hedge fund managing over $36B in assets at its peak. Archegos collapsed when it couldn't repay its lenders. Banks, including Credit Suisse, Nomura (NYSE:NMR), Morgan Stanley (MS) and UBS (NYSE:UBS), suffered more than $10B in losses. Shareholder losses in Archegos' portfolio companies totaled over $100B.

Prosecutors in the Justice Department's criminal antitrust division have revived a stalled probe into how Hwang's lenders unwound over $150B in trades made by his family office, Bloomberg reported, citing people familiar with the matter.

Following Hwang's fraud trial, the San Francisco office of the DOJ has renewed its investigation, concentrating on the urgent meetings banks held in March 2021, the people added. At these gatherings, participants discussed strategies for a coordinated sell-off of their client's portfolio to limit their financial exposure.

The DOJ is probing whether there was collusion or a conspiracy to collude to control prices in those discussions, the article said. Credit Suisse, Nomura (NMR) and UBS (UBS) were said to have reached a managed liquidation agreement to offload parts of their Archegos exposure. Other banks like Goldman Sachs (GS), Morgan Stanley (MS) and Deutsche Bank (DB) had explored such a deal, only to decide against it.

More on the Archegos Fallout

  • Archegos Capital was forced to sell more than $20B in stocks on Friday
  • Morgan Stanley sold $5B in shares of Archegos stocks night before block sales
  • Credit Suisse takes $4.7B hit from Archegos disaster, slashes dividend

     

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。